Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells (Journal of Cellular Physiology (2008) 216, (698-707) DOI: 10.1002/jcp.21444);Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

Journal of Cellular Physiology

Volumn 216, Issue 3, 2008, Pages 698-707

  Cascone, Tina ^a,b   Morelli, Maria Pia ^a   Morgillo, Floriana ^a   Kim, Woo Young ^b   Rodolico, Gabriella ^a   Pepe, Stefano ^c   Berrino, Liberato ^a   Lee, Ho Young ^b   Heymach, John V ^b   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME INHIBITOR; PROTEIN KINASE B; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HCT116; COLON ADENOCARCINOMA; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MONOTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 48749110809     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21540     Document Type: Erratum

References (40)

1. Adams J. 2004. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360.
2. An J, Rettig MB. 2007. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6:61-69.
3. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. 2003. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822.
4. Bross PF, Kane R, Farrell AT, Abraham S, Bensen K, Brown ME, Bradley S, Gobburu JV, Goheer A, Lee SL, Leighton J, Liang Cy, Lostritto RT, et al. 2004. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10:3954-3964.
5. Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V. 2004. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 5:148-157.
6. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M. 2002. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290.
7. Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, Kousteni S, Bellido T, Manolagas SC. 2005. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J Biol Chem 280:4632-4638.
8. Chou TC, Talaly P. 1977. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252:6438-6442.
9. Chun KH, Kosmeder JW II, Sun S, Pezzuto JM, Lotan R, Hong WK, Lee HY. 2003. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 9S:291-302.
10. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. 2001. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465.
11. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. 2003. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-1556.
12. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J. 2006. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5:665-675.
13. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
14. Fedi P, Pierce JH, di Fiore PP, Kraus MH. 1994. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 14:492-500.
15. Franke TF, Yang SI, Chan TO, Datta K, Kaslauskas A, Morrison DK, Kaplan DR, Tsichilis PN. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736.
16. Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N. 2006. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 17:455-462.
17. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. 2004. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355-5362.
18. Ji L, Nishizaki M, Gao B, Burbee D, Kendo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Feng B, Lerman MI, Roth JA, Minna JD. 2002. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62:2715-2720.
19. Lenz HJ. 2003. Clinical update: Proteasome inhibitors in solid tumors. Cancer Treat Rev 29:41-48.
20. Lorch JH, Thomas TO, Schmoll HJ. 2007. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67:727-734.
21. Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
22. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J. 2004. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501.
23. Morelli MP, Cascone T, Troiani T, Morgillo F, Martinelli E, De Vita F, Eckhardt SG, Ciardiello F. 2005. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16:iv61-iv70.
24. Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Placido S, Tortora G, Ciardiello F. 2006. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208:344-353.
25. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. 2003. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 10:1-21.
26. Olayioye MA, Neve RM, Lane HA, Hynes NE. 2000. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167.
27. Orlowski RZ, Dees EC. 2003. The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5:1-7.
28. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. 2005. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639.
29. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkamur SV, Srklalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, et al. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
30. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. 2006. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184-191.
31. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J. 2000. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 20:1448-1459.
32. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
33. Schroeder CP, Kadara H, Lotan D, Woo JK, Lee HY, Hong WK, Lotan R. 2006. Involvement of mitochondrial and akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 66:9762-9770.
34. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152.
35. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG. 2006. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther S:1883-1894.
36. Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco AR, Tortora G, Ciardiello F. 2005. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 11:1268-1276.
37. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrow HL, Graham GA, Hughes GD, et al. 2002. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655.
38. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
39. Ying WZ, Zhang HG, Sanders PW. 2007. EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J Am Soc Nephrol 18:131-142.
40. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. 2001. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252.